- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Case report: Successful induction of buprenorphine/naloxone...
Open Collections
UBC Faculty Research and Publications
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach Rozylo, Jennifer; Mitchell, Keren; Nikoo, Mohammadali; Durante, S. E.; Barbic, Skye; Lin, Daniel; Mathias, Steve; Azar, Pouya
Abstract
Background: The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation: We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine/naloxone microdosing schedule, we initiated treatment of an individual’s opioid use disorder. There was a successful buprenorphine/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine/naloxone. Including the induction period, the medication was used consistently for 4 weeks. Conclusions: A microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.
Item Metadata
Title |
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach
|
Creator | |
Contributor | |
Publisher |
BioMed Central
|
Date Issued |
2020-01-15
|
Description |
Background:
The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction.
Case presentation:
We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk patient with a history of failed initiations due, in part, to withdrawal symptoms. Using an assertive outreach model and a buprenorphine/naloxone microdosing schedule, we initiated treatment of an individual’s opioid use disorder. There was a successful buprenorphine/naloxone microdosing induction as the team reached a therapeutic dose of buprenorphine/naloxone. Including the induction period, the medication was used consistently for 4 weeks.
Conclusions:
A microdosing schedule can be used to induce a patient onto buprenorphine/naloxone with no apparent withdrawal; gradually reducing illicit substance use. This case report builds on previous literature, highlighting ways to minimize barriers to induction of buprenorphine/naloxone, using a microdosing schedule and assertive outreach. Given the safety profile of buprenorphine and its potential to be a lifesaving intervention, a larger study of microdosing is indicated.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2020-01-16
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0388312
|
URI | |
Affiliation | |
Citation |
Addiction Science & Clinical Practice. 2020 Jan 15;15(1):2
|
Publisher DOI |
10.1186/s13722-020-0177-x
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty
|
Copyright Holder |
The Author(s)
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)